Dengue vaccine-induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  JCI Insight

• Publication date

  2017-12-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1172/jci.insight.94500PMID 29263304PMCID PMC5752305
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis

  2017cited by this paper
• Molecular determinants of plaque size as an indicator of dengue virus attenuation

  2016cited by this paper
• A Tetravalent Formulation Based on Recombinant Nucleocapsid-like Particles from Dengue Viruses Induces a Functional Immune Response in Mice and Monkeys

  2016cited by this paper
• Projections of increased and decreased dengue incidence under climate change

  2016cited by this paper
• Maternal Antibody-Mediated Disease Enhancement in Type I Interferon-Deficient Mice Leads to Lethal Disease Associated with Liver Damage

  2016cited by this paper
• Protective Role of Cross-Reactive CD8 T Cells Against Dengue Virus Infection

  2016cited by this paper
• Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.

  2015cited by this paper
• Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.

  2015cited by this paper
• Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity

  2015cited by this paper
• Mouse models of dengue virus infection for vaccine testing.

  2015cited by this paper
• Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice

  2015cited by this paper
• The dengue vaccine pipeline: Implications for the future of dengue control.

  2015cited by this paper
• Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.

  2015cited by this paper
• CD8+ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate.

  2015cited by this paper
• CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice

  2015cited by this paper
• CD8+ T Cells Prevent Antigen-Induced Antibody-Dependent Enhancement of Dengue Disease in Mice

  2014cited by this paper
• Dengue Virus Neutralizing Antibody Levels Associated with Protection from Infection in Thai Cluster Studies

  2014cited by this paper
• The Human CD8+ T Cell Responses Induced by a Live Attenuated Tetravalent Dengue Vaccine Are Directed against Highly Conserved Epitopes

  2014cited by this paper
• Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice.

  2014cited by this paper
• First Experimental In Vivo Model of Enhanced Dengue Disease Severity through Maternally Acquired Heterotypic Dengue Antibodies

  2014cited by this paper
• Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera

  2014cited by this paper
• Maternal Antibodies: Clinical Significance, Mechanism of Interference with Immune Responses, and Possible Vaccination Strategies

  2014cited by this paper
• Functional Analysis of Antibodies against Dengue Virus Type 4 Reveals Strain-Dependent Epitope Exposure That Impacts Neutralization and Protection

  2013cited by this paper
• Role of Humoral versus Cellular Responses Induced by a Protective Dengue Vaccine Candidate

  2013cited by this paper
• The Type-Specific Neutralizing Antibody Response Elicited by a Dengue Vaccine Candidate Is Focused on Two Amino Acids of the Envelope Protein

  2013cited by this paper
• Synergistic Induction of Interferon α through TLR-3 and TLR-9 Agonists Identifies CD21 as Interferon α Receptor for the B Cell Response

  2013cited by this paper
• Epidemiology of dengue: past, present and future prospects

  2013cited by this paper
• Dengue vaccines: recent developments, ongoing challenges and current candidates

  2013cited by this paper
• Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells

  2013cited by this paper
• Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.

  2012cited by this paper
• Conservation of the DENV-2 type-specific and DEN complex-reactive antigenic sites among DENV-2 genotypes.

  2012cited by this paper
• Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

  2012cited by this paper
• Primary Vaccination with Low Dose Live Dengue 1 Virus Generates a Proinflammatory, Multifunctional T Cell Response in Humans

  2012cited by this paper
• Expression and immunoaffinity purification of recombinant dengue virus 2 NS1 protein as a cleavable SUMOstar fusion.

  2012cited by this paper
• Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

  2012cited by this paper
• Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice.

  2012cited by this paper
• Differential Targeting of Viral Components by CD4+ versus CD8+ T Lymphocytes in Dengue Virus Infection

  2012cited by this paper
• Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection.

  2011cited by this paper
• Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.

  2011cited by this paper
• Impairment of CD4+ T cell polarization by dengue virus-infected dendritic cells.

  2011cited by this paper
• A Single Amino Acid in Nonstructural Protein NS4B Confers Virulence to Dengue Virus in AG129 Mice through Enhancement of Viral RNA Synthesis

  2011cited by this paper
• Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans

  2010cited by this paper
• The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1

  2010cited by this paper
• Structure and Function Analysis of Therapeutic Monoclonal Antibodies against Dengue Virus Type 2

  2010cited by this paper
• The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.

  2010cited by this paper
• Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses

  2010cited by this paper
• A Non Mouse-Adapted Dengue Virus Strain as a New Model of Severe Dengue Infection in AG129 Mice

  2010cited by this paper
• CD4 T Cells Are Not Required for the Induction of Dengue Virus-Specific CD8 T Cell or Antibody Responses but Contribute to Protection after Vaccination

  2010cited by this paper
• Correlates of Protection Induced by Vaccination

  2010cited by this paper
• Antigen specific killing assay using CFSE labeled target cells.

  2010cited by this paper
• CD4+ T Cells Are Not Required for the Induction of Dengue Virus-Specific CD8+ T Cell or Antibody Responses but Contribute to Protection after Vaccination

  2010cited by this paper
• Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance.

  2009cited by this paper
• Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens

  2009cited by this paper
• A Protective Role for Dengue Virus-Specific CD8+ T Cells 1

  2009cited by this paper
• Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus

  2008cited by this paper
• Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II

  2008cited by this paper
• Clinical and laboratory features that distinguish dengue from other febrile illnesses in endemic populations

  2008cited by this paper
• Conservation and Variability of Dengue Virus Proteins: Implications for Vaccine Design

  2008cited by this paper
• T-cell quality in memory and protection: implications for vaccine design

  2008cited by this paper
• The CD8 T-Cell Response against Murine Gammaherpesvirus 68 Is Directed toward a Broad Repertoire of Epitopes from both Early and Late Antigens

  2008cited by this paper
• Maternal antibody and viral factors in the pathogenesis of dengue virus in infants.

  2007cited by this paper
• Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes

  2007cited by this paper
• An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice

  2007cited by this paper
• T Cell Responses in Dengue Hemorrhagic Fever: Are Cross-Reactive T Cells Suboptimal?1

  2006cited by this paper
• Recombinant, Live-Attenuated Tetravalent Dengue Virus Vaccine Formulations Induce a Balanced, Broad, and Protective Neutralizing Antibody Response against Each of the Four Serotypes in Rhesus Monkeys

  2005cited by this paper
• Altered Cytokine Responses of Dengue-Specific CD4+ T Cells to Heterologous Serotypes 1

  2005cited by this paper
• Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.

  2004cited by this paper
• Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever

  2003cited by this paper
• Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

  2003cited by this paper
• CD8 T cell responses to infectious pathogens.

  2003cited by this paper
• Vaccines: Effector and memory T-cell differentiation: implications for vaccine development

  2002cited by this paper
• Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections.

  2002cited by this paper
• Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren.

  2002cited by this paper
• Dengue Hemorrhagic Fever in Infants: Research Opportunities Ignored

  2002cited by this paper
• Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.

  2001cited by this paper
• New Mouse Model for Dengue Virus Vaccine Testing

  1999cited by this paper
• Neutralizing Antibodies Protect against Lethal Flavivirus Challenge but Allow for the Development of Active Humoral Immunity to a Nonstructural Virus Protein

  1998cited by this paper
• Virus-specific CD8+ T cells in primary and secondary influenza pneumonia.

  1998cited by this paper
• Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the Epstein-Barr Virus–induced Cytotoxic T Cell Response

  1997cited by this paper
• Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers.

  1996cited by this paper
• Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

  1994cited by this paper
• Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity

  1989cited by this paper
• Gamma interferon augments Fc gamma receptor-mediated dengue virus infection of human monocytic cells

  1988cited by this paper
• Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers.

  1987cited by this paper

• From promise to pitfalls: immunological lessons from dengue vaccines and their implications.

  2026cites this paper
• Challenges and Opportunities in the Development of Dengue Vaccines: A Comprehensive Review

  2026cites this paper
• Glycans on non-structural protein 1 prevent premature T-cell mediated dengue virus clearance

  2025cites this paper
• Enhanced durability of a Zika virus self-amplifying RNA vaccine through combinatorial OX40 and 4-1BB agonism

  2025cites this paper
• Dysregulated immune cell responses in severe dengue pathogenesis

  2025cites this paper
• De-glycosylated non-structural protein 1 enhances dengue virus clearance by limiting PD-L1/PD-1 mediated T cell apoptosis

  2024cites this paper
• Exploring Dengue Infection in a Vaccinated Individual: Preliminary Molecular Diagnosis and Sequencing Insights

  2024cites this paper
• Zika virus T-cell based 704/DNA vaccine promotes protection from Zika virus infection in the absence of neutralizing antibodies

  2024cites this paper
• Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses

  2023cites this paper
• A chimeric classical insect-specific flavivirus provides complete protection against West Nile virus lethal challenge in mice.

  2023cites this paper
• Recombinant Modified Vaccinia Virus Ankara Expressing a Glycosylation Mutant of Dengue Virus NS1 Induces Specific Antibody and T-Cell Responses in Mice

  2023cites this paper
• Dengue in Pregnancy: A Southeast Asian Perspective

  2023cites this paper
• Intermediate Levels of Pre-Existing Protective Antibody Allow Priming of Protective T Cell Immunity against Influenza.

  2023cites this paper
• Infection order outweighs the role of CD4+ T cells in tertiary flavivirus exposure

  2022cites this paper
• Infection order outweighs the role of CD4+ T cells in tertiary flavivirus infection

  2022cites this paper
• Zika virus infection during pregnancy protects against secondary infection in the absence of CD8+ cells

  2021cites this paper
• A single-dose live attenuated chimeric vaccine candidate against Zika virus

  2021cites this paper
• Targeting the Annexin A1-FPR2/ALX pathway for host-directed therapy in dengue disease

  2021cites this paper
• A single-dose live attenuated chimeric vaccine candidate against Zika virus

  2021cites this paper
• Cross-serotypically conserved epitope recommendations for a universal T cell-based dengue vaccine

  2020cites this paper
• Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1

  2020cites this paper
• An update on dengue vaccine development, challenges, and future perspectives

  2020cites this paper
• Multifunctional T cell response in convalescent patients two years after ZIKV infection

  2020cites this paper
• A perspective on potential antibody-dependent enhancement of SARS-CoV-2

  2020cites this paper
• Japanese encephalitis virus–primed CD8+ T cells prevent antibody-dependent enhancement of Zika virus pathogenesis

  2020cites this paper
• The effect of maternal antibodies on the cellular immune response after infant vaccination: A review.

  2020influential citation
• Zika virus infection during pregnancy protects against secondary infection in the absence of CD8+ cells

  2020cites this paper
• Vaccines against COVID-19

  2020cites this paper
• Conserved epitopes with high HLA-I population coverage are targets of CD8+ T cells associated with high IFN-γ responses against all dengue virus serotypes

  2020cites this paper
• Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development

  2020cites this paper
• Vaccine development

  2019cites this paper
• Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine?

  2019cites this paper
• Cross-Protection Against Four Serotypes of Dengue Virus in Mice Conferred by a Zika DNA Vaccine

  2019cites this paper
• Vaccination With a Single Consensus Envelope Protein Ectodomain Sequence Administered in a Heterologous Regimen Induces Tetravalent Immune Responses and Protection Against Dengue Viruses in Mice

  2019cites this paper
• Recent advances in understanding dengue

  2019cites this paper
• Dengue envelope-based ‘four-in-one’ virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice

  2018cites this paper
• Memory T Cells in Flavivirus Vaccination

  2018cites this paper
• Dengue: a growing threat requiring vaccine development for disease prevention

  2018cites this paper